Fig. 4From: Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) databaseThe number of AEs related to deutetrabenazine at the SOC level in the FAERS databaseBack to article page